share_log

BridGene Biosciences Announces Dosing of First Patient in Phase 1 Study Evaluating Novel TEAD Inhibitor BGC515 in Advanced Solid Tumors

BridGene Biosciences Announces Dosing of First Patient in Phase 1 Study Evaluating Novel TEAD Inhibitor BGC515 in Advanced Solid Tumors

BridGene生物科技宣佈對於愛文思控股腫瘤領域的新藥BGC515進行第一階段研究,評估其TEAD抑制劑的效果。
PR Newswire ·  06/28 07:33

SAN JOSE, Calif., June 28, 2024 /PRNewswire/ -- BridGene Biosciences, Inc., a leader in developing covalent small molecule drugs for traditional "hard-to-drug" targets, announced today that the first patient has been dosed in its Phase 1 clinical trial of BGC515, a novel TEAD inhibitor discovered through BridGene's cutting-edge chemoproteomic platform, IMTAC. This milestone highlights the potential of BridGene's innovative chemoproteomics approach.

加利福尼亞州聖何塞,2024年6月28日/美通社/--BridGene Biosciences,Inc.宣佈,通過其最先進的IMTAC化學蛋白質組學平台,開發出針對傳統難以治療的靶點的共價小分子藥物BGC515,今日該藥物已在一期臨床實驗中給予首位患者劑量,該里程碑突顯了BridGene創新的蛋白質組學化學療法的潛力。

The Phase 1 study will enroll subjects in both the US and China (NCT06452160) to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of BGC515 as a single agent in patients with advanced solid tumors, including malignant mesothelioma, epithelioid hemangioendothelioma, and other solid tumors with hippo pathway dysregulation. Dr. Timothy Yap, Ph.D., FRCP, Professor in the Department of Investigational Cancer Therapeutics (Phase I Program) and Head of Clinical Development, Therapeutics Discovery Division at the University of Texas MD Anderson Cancer Center, is the principal investigator at the initial US site, where the first patient has been enrolled.

該一期研究將在美國和中國(NCT06452160)招募受試者,評估BGC515作爲單一製劑對具有Hippo信號通路失調的晚期實體瘤,包括惡性間皮瘤、上皮內血管內皮瘤和其他實體瘤的安全性、耐受性、藥代動力學、藥效動力學和初步抗腫瘤活性。這項研究的首席研究員是德克薩斯大學MD安德森癌症中心臨床開發總負責人、調查性癌症治療系學院的Timothy Yap博士,他將在美國的首個研究臨床站招募首批患者。

"We are delighted to begin the clinical evaluation of BGC515 with the dosing of our first patient, and we look forward to the evaluation of the initial safety and efficacy of this exciting compound," said Jeremy Barton, M.D., Chief Medical Officer of BridGene Biosciences.

“BridGene非常高興通過給首位患者劑量方式開始BGC515的臨床評估,我們期待着首批藥物安全性和療效的評價,”BridGene Biosciences首席醫學官Jeremy Barton博士說道。

"The initiation and dosing of our first drug in clinical development from our chemoproteomic platform marks a major inflection point for BridGene," stated Ping Cao, Ph.D., Co-Founder and CEO of BridGene Biosciences. "This achievement underscores our commitment to addressing unmet medical needs through innovative therapeutic solutions. BGC515 represents a breakthrough in targeting the TEAD proteins, a critical component in the Hippo signaling pathway. We are proud of the progress we have made in a short time, developing a pipeline that includes previously undruggable targets for prominent oncology and immunology diseases."

BridGene Biosciences的聯合創始人兼首席執行官Ping Cao博士表示:“通過我們的化學蛋白質組學平台開始藥品開發並給首批患者進行劑量是BridGene的一個重要拐點。這個成果突顯了我們通過創新的治療方案來解決未滿足的醫療需求的承諾。BGC515是一種能夠靶向TEAD蛋白的突破性藥物,這是Hippo信號傳導途徑的重要組成部分。在短時間內,我們以包括之前無法治癒的突出腫瘤和免疫學疾病在內的重要領域開發了一系列藥物。”

BridGene Biosciences is advancing multiple novel drug discovery programs toward the clinic and has over a dozen similar opportunities emerging in early discovery.

BridGene Biosciences正在推進多個新型藥物發現項目,已有超過一打類似機會在早期研究中浮現。

About the Hippo Pathway and BGC515
The Hippo pathway is a key pathway used by cells to control expression of a group of genes by regulating activity of transcription factors YAP and TAZ. YAP and TAZ function in a complex with partner proteins, the TEADs, which are the targets of BGC515. A variety of human cancers depend on activation of YAP and TAZ, which can occur by various mechanisms.

關於Hippo通路和BGC515
Hippo信號通路是細胞控制一組基因表達的關鍵途徑,通過調節轉錄因子YAP和TAZ的活性來發揮其作用。YAP和TAZ與夥伴蛋白TEAD複合物一起發揮作用,TEAD是BGC515的靶點。多種人類癌症依賴於YAP和TAZ的激活,這可以通過多種機制實現。

BGC515 is an internally-developed, orally-administered, covalent TEAD inhibitor.

BGC515是一種內部開發的口服共價TEAD抑制劑。

About BridGene Biosciences
BridGene is a biotechnology company focused on discovering and developing innovative small molecules that drug traditionally undruggable targets, providing new paths to treat diseases. By using its proprietary chemoproteomic platform, IMTAC, BridGene is able to screen small molecules against all proteins in live cells to discover drug candidates for high value and previously undruggable targets. For this purpose, BridGene takes advantage of its proprietary, diverse covalent library of tagged, drug-like small molecules. The ultimate goal is to enable breakthrough small-molecule drug discovery and to expand the mechanisms to treat diseases, with targets previously inaccessible to small molecules. BridGene is advancing a diversified pipeline of first-in-class drugs for targets in multiple disease areas. For more information, visit

關於BridGene Biosciences
BridGene是一家生物技術公司,專注於發現和開發創新的小分子藥物,用於治療傳統上難以治療的靶點,爲治療疾病提供新的途徑。通過使用其專有的IMTAC化學蛋白質組學平台,BridGene能夠篩選小分子藥物對所有活細胞中的蛋白分子進行篩選,以發現高價值和先前難以開發的靶點的藥物候選物。爲此,BridGene利用其專有的多樣性共價標記,藥物類小分子化學庫。最終目標是實現突破式的小分子藥物發現並擴展治療疾病的機制,包括以前無法治癒的靶點。BridGene正在向多種疾病領域的靶點推進首創性藥物的多樣化管道。更多信息請訪問

Contact
Tiberend Strategic Advisors, Inc.
Daniel Kontoh-Boateng (investors)
862-213-1398
[email protected]

聯繫人
泰博倫德戰略顧問公司。
丹尼爾·康託博滕(投資者)
862-213-1398
[email protected]

Dave Schemelia (media)
[email protected]
609-468-9325

戴夫·謝梅利亞(媒體)
[email protected]
609-468-9325

SOURCE BridGene Biosciences

出處:BridGene生物科技公司

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論